ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer

BACKGROUND: Immunotherapy with checkpoint inhibitors (CI) represents an important novel development in cancer treatment. Metastatic triple-negative breast cancer (mTNBC) is incurable, with a median survival of only ~ 13 months. We have initiated the randomized placebo-controlled phase IIb study ALIC...

Descripción completa

Detalles Bibliográficos
Autores principales: Kyte, J. A., Røssevold, A., Falk, R. S., Naume, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310523/
https://www.ncbi.nlm.nih.gov/pubmed/32576225
http://dx.doi.org/10.1186/s12967-020-02424-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310523/
https://www.ncbi.nlm.nih.gov/pubmed/32576225
http://dx.doi.org/10.1186/s12967-020-02424-7

Ejemplares similares